Population study: one-time survey
Original title: Clinical validation of C12FDG as a marker associated with senescence and osteoarthritic phenotypes.
Points to benefit
Worn-out blood cells rose with age and in osteoarthritis. The share of these cells and age-linked blood markers were lower in a small subgroup taking fisetin. The abstract gives no group size.
✓ Strength– Limit• Note
These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.
Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.
↑ Stronger evidence
Not done yet. This is the step that would answer the question.
None among the papers we read.
None among the papers we read.
None among the papers we read.
↓ Weaker evidence
The short answer to “Does fisetin slow aging?”
Not shown in people.
Confidence: very low. Based on 12 on-topic papers.
Read the full answerFew other papers sit on the same step, so there is little to compare it with.
None among the papers we read.
See all 12 studies on this questionSpot an error? Email a flag with a link to your source, or use the form on the question page.